Literature DB >> 8815959

Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.

C K Meshul1, O A Andreassen, C Allen, H A Jørgensen.   

Abstract

Long-term treatment with the typical antipsychotic drug, haloperidol, can lead to a sometimes irreversible motor disorder, tardive dyskinesia (TD). It has been hypothesized that increased release of glutamate due to prolonged neuroleptic drug treatment may result in an excitotoxic lesion in specific neuronal populations within the basal ganglia, leading to TD. We reported that treatment with haloperidol for 1 month results in an increase in the mean percentage of striatal asymmetric synapses containing a perforated postsynaptic density (PSD) and that these synapses are glutamatergic. Using quantitative immunocytochemistry, we found that depending on how long the animals had been off haloperidol following subchronic (30 d) treatment, there was either a decrease (1 day off) or increase (3-4 days off) in the density of glutamate immunolabeling within the presynaptic terminals of synapses with perforated PSDs. Using a rat model for TD, animals in the current study were treated for 1 year with haloperidol and spontaneous oral dyskinesias (i.e. vacuous chewing movements, VCMs) were recorded. In these long-term treated animals we wanted to determine if there was a correlation between glutamate function, as measured by changes in synapses with perforated PSDs and the density of nerve terminal glutamate immunoreactivity, and VCM behavior. In drug treated rats which demonstrated either a high or low rate of VCMs, there was a significant increase in the mean percentage of asymmetric synapses in the dorsolateral striatum with perforated PSDs in both haloperidol-treated groups compared to vehicle-treated rats. There was a small but significant increase in the density of glutamate immunolabeling within striatal nerve terminals of the high VCM group compared to the low VCM group. There was, however, no difference in the density of glutamate immunolabeling between the high VCM group compared to the vehicle-treated animals. One reason for this lack of difference was partially due to a significant increase in nerve terminal area within the high VCM group compared to either the low VCM- or vehicle-treated groups. The larger nerve terminal size in the high VCM group may be due to a small but sustained increase in glutamate neurotransmitter release with the ability of the terminal to maintain its supply of glutamate, while the terminals in the low VCM group showed evidence of glutamate depletion. This finding would be consistent with the hypothesis that increased glutamatergic activity may be associated with TD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8815959     DOI: 10.1007/bf02247334

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  Induction of long-term potentiation is associated with an increase in the number of axospinous synapses with segmented postsynaptic densities.

Authors:  Y Geinisman; L deToledo-Morrell; F Morrell
Journal:  Brain Res       Date:  1991-12-06       Impact factor: 3.252

2.  Dynamic changes in the dendritic geometry of individual neurons visualized over periods of up to three months in the superior cervical ganglion of living mice.

Authors:  D Purves; R D Hadley; J T Voyvodic
Journal:  J Neurosci       Date:  1986-04       Impact factor: 6.167

Review 3.  Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).

Authors:  O Hornykiewicz
Journal:  Br Med Bull       Date:  1973-05       Impact factor: 4.291

4.  Quantification of immunogold labelling reveals enrichment of glutamate in mossy and parallel fibre terminals in cat cerebellum.

Authors:  P Somogyi; K Halasy; J Somogyi; J Storm-Mathisen; O P Ottersen
Journal:  Neuroscience       Date:  1986-12       Impact factor: 3.590

5.  Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenithixol) in rats.

Authors:  E B Nielsen; M Lyon
Journal:  Psychopharmacology (Berl)       Date:  1978-09-15       Impact factor: 4.530

6.  Extracellular concentrations of aspartate and glutamate in rat neostriatum following chemical stimulation of frontal cortex.

Authors:  A M Palmer; P H Hutson; S L Lowe; D M Bowen
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

7.  GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats.

Authors:  O A Andreassen; H A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

8.  Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias.

Authors:  M F Egan; Y Hurd; T M Hyde; D R Weinberger; R J Wyatt; J E Kleinman
Journal:  Synapse       Date:  1994-11       Impact factor: 2.562

9.  Glutamine and aspartate loading of synaptosomes: a reevaluation of effects on calcium-dependent excitatory amino acid release.

Authors:  H T McMahon; D G Nicholls
Journal:  J Neurochem       Date:  1990-02       Impact factor: 5.372

10.  Evidence for recycling of synaptic vesicle membrane during transmitter release at the frog neuromuscular junction.

Authors:  J E Heuser; T S Reese
Journal:  J Cell Biol       Date:  1973-05       Impact factor: 10.539

View more
  9 in total

Review 1.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

2.  Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias.

Authors:  G E Meredith; I E De Souza; T M Hyde; G Tipper; M L Wong; M F Egan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

3.  Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study.

Authors:  Lesley A McCollum; Courtney K Walker; Joy K Roche; Rosalinda C Roberts
Journal:  Schizophr Bull       Date:  2015-03-27       Impact factor: 9.306

4.  Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat.

Authors:  Matthew L MacDonald; Molly E Eaton; Joshua T Dudman; Christine Konradi
Journal:  Biol Psychiatry       Date:  2005-05-01       Impact factor: 13.382

Review 5.  Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.

Authors:  J Fang; J W Gorrod
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

6.  Haloperidol Selectively Remodels Striatal Indirect Pathway Circuits.

Authors:  Luke E Sebel; Steven M Graves; C Savio Chan; D James Surmeier
Journal:  Neuropsychopharmacology       Date:  2016-08-31       Impact factor: 7.853

7.  Effect of chronic treatment of haloperidol on the rat liver: a stereological and histopathological study.

Authors:  Zekai Halici; Hakan Dursun; Osman Nuri Keles; Ersan Odaci; Halis Suleyman; Nazan Aydin; Elif Cadirci; Yildiray Kalkan; Bunyami Unal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-21       Impact factor: 3.000

8.  Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations.

Authors:  Etsuko Usuki; Jeffrey R Bloomquist; Ethan Freeborn; Kay Casagnoli; Cornelis J Van Der Schyf; Neal Castagnoli
Journal:  Neurotox Res       Date:  2002-02       Impact factor: 3.911

Review 9.  Relevance of animal models to human tardive dyskinesia.

Authors:  Pierre J Blanchet; Marie-Thérèse Parent; Pierre H Rompré; Daniel Lévesque
Journal:  Behav Brain Funct       Date:  2012-03-09       Impact factor: 3.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.